2SPD-029 Off-label drugs: use analysis and pharmacoepidemiology in a COVID centre in Rome

G Gambarelli, G Gambarelli, L Fiorito, R De Feo
2021 Section 2: Selection, procurement and distribution   unpublished
Conclusion and relevance BM expenditure increased by more than 50% in the last five years, with MAb being mainly responsible. The biological active substances with the highest budgetary impact were medicines to treat immune mediated diseases. The incorporation of BS will lead to a reduction of 20% in BM costs.
doi:10.1136/ejhpharm-2021-eahpconf.12 fatcat:fuz3aw4bhjbinlntekgkkwvus4